Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Debbie S. Deben"'
Autor:
Debbie S. Deben, Rob H. Creemers, Arjan J. van Adrichem, Roosmarie Drent, Audrey H. H. Merry, Mathie P. G. Leers, Adriaan A. van Bodegraven, Dennis R. Wong
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The thiopurine derivatives azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) remain standard treatment of inflammatory bowel disease (IBD). The immune suppressive effect of thiopurines is primarily based on blocking the Ras-related
Externí odkaz:
https://doaj.org/article/86bc34ef56764200be389c6b655d2aa3
Autor:
Debbie S. Deben, Luc J. J. Derijks, Bianca J. C. van den Bosch, Rob H. Creemers, Annick van Nunen, Adriaan A. van Bodegraven, Dennis R. Wong
Publikováno v:
Metabolites, Vol 13, Iss 10, p 1054 (2023)
Tioguanine is metabolised by fewer enzymatic steps compared to azathioprine and mercaptopurine, without generating 6-methylmercaptopurine ribonucleotides. However, thiopurine S-methyl transferase (TPMT) plays a role in early toxicity in all thiopurin
Externí odkaz:
https://doaj.org/article/5fbf9405476044e988f385599d3ddcd0
Autor:
Sofia A. W. van Moorsel, Debbie S. Deben, Rob H. Creemers, Bjorn Winkens, Paul Bus, Marieke J. Pierik, Melek Simsek, Nanne K. H. de Boer, Adriaan A. van Bodegraven, Dennis R. Wong
Publikováno v:
van Moorsel, S A W, Deben, D S, Creemers, R H, Winkens, B, Bus, P, Pierik, M J, Simsek, M, de Boer, N K H, van Bodegraven, A A & Wong, D R 2022, ' Predictive Algorithm for Thiopurine-Induced Hepatotoxicity in Inflammatory Bowel Disease Patients ', Therapeutic Drug Monitoring, vol. 44, no. 6, pp. 747-754 . https://doi.org/10.1097/FTD.0000000000001031
Therapeutic Drug Monitoring, 44(6), 747-754. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 44(6), 747-754. Lippincott Williams and Wilkins
Therapeutic Drug Monitoring, 44(6), 747-754. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 44(6), 747-754. Lippincott Williams and Wilkins
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathioprine (AZA) or mercaptopurine (MP) therapy within 3 months of treatment initiation due to adverse drug reactions. Of these side-effects, about half are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1762b9e57e970c9f0c6f875b45af6234
http://www.scopus.com/inward/record.url?scp=85141934898&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85141934898&partnerID=8YFLogxK
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 17:1433-1444
Despite new treatment options for inflammatory bowel disease (IBD), conventional thiopurines remain a common treatment option for maintaining remission, particularly in non-Westernized countries. Therapeutic drug monitoring (TDM) is advised in standa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04dd805f41b3e4a99ddc8e6d1157116b
https://doi.org/10.1080/17425255.2021.2029406
https://doi.org/10.1080/17425255.2021.2029406
Autor:
Mathie P.G. Leers, Sabine Puts, Kelly E J M Pelzer, Roosmarie J. M. Drent, Debbie S. Deben, Dennis R Wong, Adriaan A van Bodegraven, Arjan J van Adrichem
Publikováno v:
Cytometry Part A. 101:167-176
Thiopurine derivatives, such as azathioprine and mercaptopurine, are standard conventional treatment options in inflammatory bowel disease (IBD). Unfortunately, approximately half of patients discontinue thiopurine therapy within 2 years. To improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c600423c110441e88c4df1ea7314ed91
https://doi.org/10.1002/cyto.a.24506
https://doi.org/10.1002/cyto.a.24506
Autor:
Samantha, Ayoub, Johnny A, Kenton, Morgane, Milienne-Petiot, Debbie S, Deben, Cristian, Achim, Mark A, Geyer, William, Perry, Igor E, Grant, Jared W, Young, Arpi, Minassian
Publikováno v:
Pharmacology Biochemistry and Behavior. 222:173499
Although antiretroviral therapy (ART) has increased the quality of life and lifespan in people living with HIV (PWH), millions continue to suffer from the neurobehavioral effects of the virus. Additionally, the abuse of illicit drugs (methamphetamine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f38ada344ec30f115685efd8cc517e
https://doi.org/10.1016/j.pbb.2022.173499
https://doi.org/10.1016/j.pbb.2022.173499
Autor:
Nanne K. H. de Boer, Hans J C Buiter, Adriaan A. van Bodegraven, Melek Simsek, Dennis R Wong, Chris J. J. Mulder, Margien L. Seinen, Matthijs van Luin, Birgit I. Lissenberg-Witte, Carmen S. Horjus, Melanie V. Bénard, Debbie S. Deben
Publikováno v:
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology and Therapeutics, 50(1), 54-65
Simsek, M, Deben, D S, Horjus, C S, Bénard, M V, Lissenberg-Witte, B I, Buiter, H J C, van Luin, M, Seinen, M L, Mulder, C J J, Wong, D R, de Boer, N K H & van Bodegraven, A A 2019, ' Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies ', Alimentary Pharmacology and Therapeutics, vol. 50, no. 1, pp. 54-65 . https://doi.org/10.1111/apt.15280
Alimentary Pharmacology and Therapeutics, 50(1), 54-65
Simsek, M, Deben, D S, Horjus, C S, Bénard, M V, Lissenberg-Witte, B I, Buiter, H J C, van Luin, M, Seinen, M L, Mulder, C J J, Wong, D R, de Boer, N K H & van Bodegraven, A A 2019, ' Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies ', Alimentary Pharmacology and Therapeutics, vol. 50, no. 1, pp. 54-65 . https://doi.org/10.1111/apt.15280
Background: Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior conventional immunomodulating therapy. Aim: To report effectiveness, safety and therapeutic drug monitoring in a cohort of patients with prolonged tioguani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4591c4e3be499a18e3b3d5904c2aa39c
https://pubmed.ncbi.nlm.nih.gov/31094013
https://pubmed.ncbi.nlm.nih.gov/31094013